Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome

Barry T. Bloom, John Kattwinkel, Robert T. Hall, Paula M. Delmore, Edmund A. Egan, J. Richard Trout, Michael Malloy, David R. Brown, Ian R. Holzman, Carl H. Coghill, Waldemar A. Carlo, Arun K. Pramanik, Mary Anne McCaffree, Paul L. Toubas, Susan Laudert, Linda L. Gratny, Kathleen B. Weatherstone, John H. Seguin, Lynne D. Willett, Gary R. Gutcher & 2 others Dawn H. Mueller, William H. Topper

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND 27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS. Design. A prospective, randomized, double-blind, multicenter clinical trial. Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm. Patients. The treatment arm enrolled infants of ≤2000 g birth weight with established RDS, and the prevention arm enrolled infants of ≤29 weeks' gestation with birth weights <1250 g. Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions. Outcome Measures. We projected a 25% reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25% reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation. Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm. In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours. There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm. Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalPediatrics
Volume100
Issue number1
DOIs
StatePublished - Jul 1997

Fingerprint

Surface-Active Agents
Lung
Oxygen
Therapeutics
Adult Respiratory Distress Syndrome
Birth Weight
beractant
calfactant
Product Labeling
Air Pressure
Pressure
Neonatal Intensive Care Units
Lung Diseases
Multicenter Studies
Chronic Disease
Air
Outcome Assessment (Health Care)
Clinical Trials
Parturition
Safety

Keywords

  • Infasurf
  • Respiratory distress syndrome
  • Surfactant
  • Survanta

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Bloom, B. T., Kattwinkel, J., Hall, R. T., Delmore, P. M., Egan, E. A., Trout, J. R., ... Topper, W. H. (1997). Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics, 100(1), 31-38. https://doi.org/10.1542/peds.100.1.31

Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. / Bloom, Barry T.; Kattwinkel, John; Hall, Robert T.; Delmore, Paula M.; Egan, Edmund A.; Trout, J. Richard; Malloy, Michael; Brown, David R.; Holzman, Ian R.; Coghill, Carl H.; Carlo, Waldemar A.; Pramanik, Arun K.; McCaffree, Mary Anne; Toubas, Paul L.; Laudert, Susan; Gratny, Linda L.; Weatherstone, Kathleen B.; Seguin, John H.; Willett, Lynne D.; Gutcher, Gary R.; Mueller, Dawn H.; Topper, William H.

In: Pediatrics, Vol. 100, No. 1, 07.1997, p. 31-38.

Research output: Contribution to journalArticle

Bloom, BT, Kattwinkel, J, Hall, RT, Delmore, PM, Egan, EA, Trout, JR, Malloy, M, Brown, DR, Holzman, IR, Coghill, CH, Carlo, WA, Pramanik, AK, McCaffree, MA, Toubas, PL, Laudert, S, Gratny, LL, Weatherstone, KB, Seguin, JH, Willett, LD, Gutcher, GR, Mueller, DH & Topper, WH 1997, 'Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome', Pediatrics, vol. 100, no. 1, pp. 31-38. https://doi.org/10.1542/peds.100.1.31
Bloom, Barry T. ; Kattwinkel, John ; Hall, Robert T. ; Delmore, Paula M. ; Egan, Edmund A. ; Trout, J. Richard ; Malloy, Michael ; Brown, David R. ; Holzman, Ian R. ; Coghill, Carl H. ; Carlo, Waldemar A. ; Pramanik, Arun K. ; McCaffree, Mary Anne ; Toubas, Paul L. ; Laudert, Susan ; Gratny, Linda L. ; Weatherstone, Kathleen B. ; Seguin, John H. ; Willett, Lynne D. ; Gutcher, Gary R. ; Mueller, Dawn H. ; Topper, William H. / Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. In: Pediatrics. 1997 ; Vol. 100, No. 1. pp. 31-38.
@article{e6295a96b81643409ed423e8f622d90b,
title = "Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome",
abstract = "Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND 27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS. Design. A prospective, randomized, double-blind, multicenter clinical trial. Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm. Patients. The treatment arm enrolled infants of ≤2000 g birth weight with established RDS, and the prevention arm enrolled infants of ≤29 weeks' gestation with birth weights <1250 g. Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions. Outcome Measures. We projected a 25{\%} reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25{\%} reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation. Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm. In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours. There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm. Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.",
keywords = "Infasurf, Respiratory distress syndrome, Surfactant, Survanta",
author = "Bloom, {Barry T.} and John Kattwinkel and Hall, {Robert T.} and Delmore, {Paula M.} and Egan, {Edmund A.} and Trout, {J. Richard} and Michael Malloy and Brown, {David R.} and Holzman, {Ian R.} and Coghill, {Carl H.} and Carlo, {Waldemar A.} and Pramanik, {Arun K.} and McCaffree, {Mary Anne} and Toubas, {Paul L.} and Susan Laudert and Gratny, {Linda L.} and Weatherstone, {Kathleen B.} and Seguin, {John H.} and Willett, {Lynne D.} and Gutcher, {Gary R.} and Mueller, {Dawn H.} and Topper, {William H.}",
year = "1997",
month = "7",
doi = "10.1542/peds.100.1.31",
language = "English (US)",
volume = "100",
pages = "31--38",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Comparison of infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome

AU - Bloom, Barry T.

AU - Kattwinkel, John

AU - Hall, Robert T.

AU - Delmore, Paula M.

AU - Egan, Edmund A.

AU - Trout, J. Richard

AU - Malloy, Michael

AU - Brown, David R.

AU - Holzman, Ian R.

AU - Coghill, Carl H.

AU - Carlo, Waldemar A.

AU - Pramanik, Arun K.

AU - McCaffree, Mary Anne

AU - Toubas, Paul L.

AU - Laudert, Susan

AU - Gratny, Linda L.

AU - Weatherstone, Kathleen B.

AU - Seguin, John H.

AU - Willett, Lynne D.

AU - Gutcher, Gary R.

AU - Mueller, Dawn H.

AU - Topper, William H.

PY - 1997/7

Y1 - 1997/7

N2 - Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND 27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS. Design. A prospective, randomized, double-blind, multicenter clinical trial. Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm. Patients. The treatment arm enrolled infants of ≤2000 g birth weight with established RDS, and the prevention arm enrolled infants of ≤29 weeks' gestation with birth weights <1250 g. Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions. Outcome Measures. We projected a 25% reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25% reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation. Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm. In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours. There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm. Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.

AB - Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND 27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS. Design. A prospective, randomized, double-blind, multicenter clinical trial. Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm. Patients. The treatment arm enrolled infants of ≤2000 g birth weight with established RDS, and the prevention arm enrolled infants of ≤29 weeks' gestation with birth weights <1250 g. Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions. Outcome Measures. We projected a 25% reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25% reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation. Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm. In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours. There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm. Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.

KW - Infasurf

KW - Respiratory distress syndrome

KW - Surfactant

KW - Survanta

UR - http://www.scopus.com/inward/record.url?scp=17644445466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644445466&partnerID=8YFLogxK

U2 - 10.1542/peds.100.1.31

DO - 10.1542/peds.100.1.31

M3 - Article

VL - 100

SP - 31

EP - 38

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -